2024
Yoshino T, Hooda N , Younan D, Muro K, Shitara K, Heinemann V,… Suh M , Reichert H , Mezzi K, Fryzek J, et al. 2024. A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. Eur J Cancer 202:113975; doi: 10.1016/j.ejca.2024.113975 . PMID: 38442645.
View Abstract
Publication: Manuscripts
Vincent M , Fitch S , Bylsma L , Thompson C , Rogers S , Britt J , Wikoff D . Integration of toxicological and epidemiological information to evaluate biological plausibility and causality of associations between inhaled formaldehyde (FA) and lymphohematopoietic (LHP) cancers. Abstract 5157, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.
View Abstract
Publication: Abstracts and Presentations
Allen B, Vincent M, Lipworth L, Panko J, Suh M , Jiang X , Mumma MT, Proctor D. Lung cancer risk and exposure to hexavalent chromium: Results of extended mortality study of workers with low level exposures and quantitative risk assessment using pooled analysis of three cohorts. Poster presentation at Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.
Publication: Abstracts and Presentations
Yoshino T, Hooda N , Younan D, Shitara K, Heinemann V,… Suh M , Reichert H , et al. 2023. 127P A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness. Ann Oncol 34(Suppl 4):S1519 [abstract]; doi :10.1016/j.annonc.2023.10.262 .
View Abstract
Publication: Abstracts and Presentations
2023
Bylsma LC , Pundole X, Ju C-H, Hooda N , Movva N , Elkhouly E, et al. 2023. Systematic literature review of the prevalence and prognostic value of delta-like ligand 3 protein expression in small cell lung cancer. Target Oncol 18(6):821-835; doi: 10.1007/s11523-023-01008-x . PMID: 37930513.
View Abstract
Publication: Manuscripts
Bylsma LC , Pundole X, Ju CH, Hooda N , Movva N , Elkhouly E, Bebb G, Fryzek J, et al. 2023. Systematic literature review of the prevalence and prognostic value of delta-like ligand 3 protein expression in small cell lung cancer. Target Oncol 18(6):821-835; doi: 10.1007/s11523-023-01008-x .
View Abstract
Publication: Manuscripts
Pundole X, Ju C-H, Bylsma LC , Hooda N , Movva N , Elkhouly E, Bebb DG, Fryzek J, et al. 2023. Prevalence of delta-like ligand 3 expression in small cell lung cancer. J Clinical Oncology 41:16_suppl e20618.
View Abstract
Publication: Abstracts and Presentations
Dalvi T, Nørgaard M, Fryzek JP, Movva N , Pedersen L, Hansen HP, et al. 2023. Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark. PLoS ONE 18(4):e0284037; doi: 10.1371/journal.pone.0284037 . PMID: 37040387.
View Abstract
Publication: Manuscripts
2022
Danese MD, Schenfeld J, Shaw J, Gawade P, Balasubramanian A, Kelsh M , et al. 2022. Association between granulocyte colony-stimulating factor (G-CSF) use and myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) among elderly patients with breast, lung, or prostate cancer. Adv Ther 39(6):2778–2795. doi:10.1007/s12325-022-02141-1.
View Abstract
Publication: Manuscripts
Danese MD, Schenfeld J, Shaw J, Gawade P, Balasubramanian A, Kelsh M , et al. 2022. Association between granulocyte colony-stimulating factor (G-CSF) use and myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) among elderly patients with breast, lung, or prostate cancer. Adv Ther 39(6):2778–2795; doi:10.1007/s12325-022-02141-1 . PMID: 35430673.
View Abstract
A Division of